RNA editing as an epitranscriptomic immune switch in tumor immunity and cancer immunotherapy

A review published in Journal of Translational Medicine argues that RNA editing, a post-transcriptional process that chemically alters RNA letters after they are copied from DNA, functions as a regulatory switch in the standoff between tumors and the immune system. The authors, led by Linlin Wen and Xuan Wang with senior investigators including Hu Ma and Jian-Guo Zhou, synthesize accumulating evidence that dysregulated RNA editing can contribute to tumor progression by impairing immune recognition, suppressing innate immune sensing and remodeling the tumor microenvironment, while programmable RNA editing tools are opening a possible path toward precision cancer immunotherapy.

The two dominant forms of RNA editing described in the review are adenosine-to-inosine (A-to-I) editing and cytidine-to-uridine (C-to-U) editing. These edits change the sequences of RNA molecules without touching the underlying genome. The result is a dynamically regulated expansion of transcriptomic diversity that can modulate cellular phenotypes, and the review presents this as consequential for cancer biology.

According to the review, RNA editing shapes tumor-immune interactions through several mechanistic channels. Protein recoding can alter the molecules a tumor cell produces. Edits also modulate innate immune signaling pathways, with the review specifically naming the MDA5/MAVS pathway. When editing levels are dysregulated, the authors report, tumors can impair immune recognition and dampen innate immune sensing. The authors further note that RNA editing interacts with other epitranscriptomic modifications, including N6-methyladenosine (m6A), placing these RNA-level changes within a broader regulatory network that influences how tumors remodel their microenvironment.

A significant portion of the review is devoted to emerging biotechnology. Programmable RNA base editing systems, such as engineered ADAR systems and Cas13-deaminase fusion-based editing platforms, together with other RNA-targeting technologies, provide new tools for precise and transient regulation at the RNA level. Unlike permanent genome editing, these approaches alter RNA rather than DNA, a property the authors highlight as having potential value for cancer immunotherapy.

The authors are careful to draw a technical boundary within this fast-moving field. Programmable RNA editing directly changes the nucleotide sequence of an RNA molecule. By contrast, Cas13-mediated RNA degradation, RNA processing and RNA vaccines do not perform RNA base editing in the strict sense, even though they are RNA-targeting technologies that may complement editing strategies. The review states that these technologies differ significantly in their mechanisms and in the maturity of their evidence, a distinction that matters for how candidates are designed and compared in translational research.

Delivery and expression platforms form a second enabling layer. The review reports that the development of RNA delivery and expression platforms has further expanded the possibilities for applying these strategies in vivo, supporting the potential of RNA-level therapeutics beyond laboratory settings.

Substantial barriers remain before any clinical use. The authors identify editing specificity, cell- and tissue-specific delivery and biosafety as the major challenges for clinical translation. Off-target edits, imperfect targeting of the right cells in the right tissues and unresolved safety questions all require further work. The review concludes that RNA editing is emerging as an important mechanism connecting tumor immune regulation and precision RNA therapy, but that further validation is needed before clinical application.

As a review article, the paper does not report new experimental efficacy data; it consolidates a growing literature and articulates a conceptual framework in which RNA editing acts as an epitranscriptomic control point for tumor immunity. Its central message is twofold: first, that dysregulated RNA editing is a documented contributor to impaired immune recognition and tumor progression in the studies surveyed, and second, that programmable RNA editing technologies, despite their immaturity, offer a reversible and tunable toolkit for intervening at the RNA level. If the specificity, delivery and biosafety challenges can be solved, the authors suggest, the chemical rewriting of RNA letters could become a genuine lever in cancer immunotherapy.

Subject of Research: RNA editing mechanisms in tumor immunity and their potential application in cancer immunotherapy

Article Title: RNA editing as an epitranscriptomic immune switch in tumor immunity and cancer immunotherapy

Article References: Wen, L., Wang, X., Cui, Y., Wang, J., Jin, S., Li, X., Wang, Y., Xu, J., Cai, Y., Chen, M., Wang, S., Ma, H., & Zhou, J.-G. (2026). RNA editing as an epitranscriptomic immune switch in tumor immunity and cancer immunotherapy. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09100-2

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09100-2

Keywords: RNA editing, A-to-I editing, C-to-U editing, ADAR, tumor microenvironment, MDA5/MAVS, m6A, epitranscriptomics, Cas13, cancer immunotherapy, RNA therapeutics, editing